Please refer to the originator’s website to learn all the information needed to use this medicine safely and effectively.
$88.00 USD – $149.00 USD
Bdaxit™ is a quality assured generic of Inlyta® used as first-line treatment of patients with advanced renal cell carcinoma (RCC) in combination with other medicines. It’s also indicated for the treatment of advanced renal cell carcinoma (RCC) in adult patients who failed 1 prior systemic therapy. It’s produced in a WHO & EMA approved factory in India.
Package Size : 28 Tablets
Active Ingredients : Axitinib 1 MG, 5 MG
Produced by BDR Pharmaceuticals Ltd®
No prescription? Do you have an old Axitinib pack with your info on it? Click here for help
Delivery of medication is fully guaranteed and takes 4 to 9 days by USPS or DHL Express